Gpx4 inhibitors, pharmaceutical compositions thereof, and their use for treating gpx4-mediated diseases
US-2024246901-A1 · Jul 25, 2024 · US
US10934259B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10934259-B2 |
| Application number | US-201716337571-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 26, 2017 |
| Priority date | Sep 28, 2016 |
| Publication date | Mar 2, 2021 |
| Grant date | Mar 2, 2021 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention relates to a novel process for preparation of boscalid anhydrate form I and boscalid anhydrate form II.
Opening claim text (preview).
The invention claimed is: 1. A process for the preparation of boscalid anhydrate form I, the process comprising (a) dissolving a boscalid starting material in dichloromethane, dichloroethane, chloroform, or chlorobenzene, at or above room temperature to provide a boscalid solution; (b) cooling the boscalid solution and stirring the solution at a speed of 400-700 rpm in a time period of 15 minutes to 2 hours until crystal formation is observed; and (c) effecting crystallization by rapid cooling to provide a solid crystalline product from the stirred solution, wherein the solution is rapidly cooled to a temperature between −10° C. to 5° C. to effect the crystallization; wherein said boscalid starting material is a mixture of boscalid anhydrate from I and boscalid anhydrate form II, or said boscalid starting material is boscalid anhydrate form II, and wherein the solid crystalline product is boscalid anhydrate form II having a melting point of 144-145° C. 2. The process of claim 1 , comprising dissolving the boscalid at a temperature between about 25° and about 120° C. in step a). 3. The process of claim 1 , wherein in step (b), cooling is to a temperature between about 20° C. and about 50° C. 4. The process of claim 1 , wherein said crystallization in step (c) is initiated by seeding the solution with boscalid anhydrate form I. 5. A process for the preparation of boscalid anhydrate form II, the process comprising (a) dissolving a boscalid starting material in dichloromethane, dichloroethane, chloroform, or chlorobenzene, at or above room temperature, (b) cooling the boscalid solution and stirring the solution at a speed of 40-130 rpm in a time period of 2 hours to 4 hours until crystal formation is observed; and (c) effecting crystallization by gradual cooling to provide a solid crystalline product from the stirred solution, wherein the solution is gradually cooled to a temperature between −10° C. to 5° C. to effect the crystallization; wherein said boscalid starting material is a mixture of boscalid anhydrate from I and boscalid anhydrate form II, or said boscalid starting material is boscalid anhydrate form I, and wherein the solid crystalline product is boscalid anhydrate form II having a melting point of 147-148° C. 6. The process of claim 5 , comprising dissolving at a temperature between about 25° and about 120° C. in step a). 7. The process of claim 5 , wherein in step (b), cooling is to a temperature between about 20° C. to about 50° C. 8. The process of claim 5 , wherein said crystallization in step (c) is initiated by seeding the boscalid solution with boscalid anhydrate form II.
Amides · CPC title
cooling by heat exchange (by evaporation of components of the mixture to be separated B01D9/0013; refrigeration machines F25B) · CPC title
Purification; Separation (separation of optically-active compounds C07B57/00); Stabilisation; Use of additives · CPC title
Crystalline forms, e.g. polymorphs · CPC title
in position 3 · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.